Enecadin

Drug Profile

Enecadin

Alternative Names: NS 7; ZK 228326

Latest Information Update: 17 Aug 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nippon Shinyaku
  • Class Neuroprotectants; Pyrimidines; Small molecules
  • Mechanism of Action Calcium channel antagonists; Calpain inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurological disorders; Stroke

Most Recent Events

  • 01 Feb 2006 Phase-II clinical trials in Stroke in Germany (unspecified route)
  • 07 Oct 2004 Enecadin has been licensed to PAION worldwide except Japan
  • 21 Jul 2003 Discontinued - Phase-II for Stroke in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top